Manufacturers report positive outcomes for risdiplam in FIREFISH Part 2 study

The study, investigating use of this orally bioavailable mRNA splicing modifier in infants aged one to seven months old with symptomatic Type 1 spinal muscular atrophy, met its primary endpoint with 29% of infants sitting without support for five seconds by month 12.